Dashboard
Company has a low Debt to Equity ratio (avg) at 0.23 times
Healthy long term growth as Net Sales has grown by an annual rate of 287.90% and Operating profit at 55.70%
With a growth in Net Profit of 46.9%, the company declared Very Positive results in Sep 26
Stock is technically in a Bearish range
With ROCE of 4.8, it has a Very Attractive valuation with a 0.8 Enterprise value to Capital Employed
Majority shareholders : Non Institution
Stock DNA
Trading & Distributors
INR 258 Cr (Micro Cap)
9.00
19
0.00%
0.15
4.12%
0.72
Total Returns (Price + Dividend) 
Astal Lab for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Astal Laboratories Ltd Valuation Shifts to Very Attractive Amid Mixed Returns
Astal Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive price level, driven primarily by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This recalibration of valuation metrics invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Trading & Distributors sector.
Read More
Astal Laboratories Ltd Falls to 52-Week Low of Rs 50.55 as Sell-Off Deepens
A 45.18% decline over the past year has culminated in Astal Laboratories Ltd hitting a fresh 52-week low of Rs 50.55 on 3 Nov 2026, despite the broader market rallying with the Sensex up 1.26% on the same day.
Read More
Five Consecutive Losses Push Astal Laboratories Ltd to a New 52-Week Low
For the fifth straight session, Astal Laboratories Ltd closed lower, breaching its 52-week low territory at Rs 60.45 on 30 Oct 2026. This persistent decline has dragged the stock down by 8.72% over the last three days alone, underperforming its sector which gained 2.24% on the same day.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSESubmission of newspaper publication of Quarterly results.
Results- Financial Results For September 30 2026.
13-Nov-2026 | Source : BSESubmission of Financial Results.
Compliances- Statement Of Deviation & Variation
13-Nov-2026 | Source : BSESubmission of statement of Deviation and variation for September 2026 quarter.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Aceso Research Labs Llp (4.59%)
Sesha Sai Nikhil Chintalapati (11.38%)
81.03%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 8.53% vs 185.11% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 46.90% vs 29.00% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 138.84% vs 782.89% in Sep 2024
Growth in half year ended Sep 2025 is 26.56% vs 9,125.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 182.27% vs 257.95% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 13.75% vs 1,066.04% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 142.88% vs 171.59% in Mar 2025
YoY Growth in year ended Mar 2026 is -9.07% vs 1,044.87% in Mar 2025